Stoke Therapeutics (NASDAQ:STOK) Trading Up 4.9% - Still a Buy?

Key Points

• Stoke Therapeutics' stock price increased by 4.9% to approximately $24.08, with a notable decline in trading volume of 47% from the average daily volume.
• Multiple brokerages have given Stoke Therapeutics a consensus rating of "Buy", with price targets ranging from $22.00 to $30.00, indicating positive analyst sentiment towards the stock.
• Stoke Therapeutics reported earnings of ($0.40) per share, exceeding analysts' expectations, though their revenue fell short of estimates at $13.82 million for the quarter.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price was up 4.9% during mid-day trading on Friday . The stock traded as high as $24.15 and last traded at $24.08. Approximately 440,107 shares traded hands during trading, a decline of 47% from the average daily volume of 826,517 shares. The stock had previously closed at $22.95.

Wall Street Analyst Weigh In

Several brokerages have issued reports on STOK. BTIG Research set a $28.00 price target on Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Wedbush lifted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.57.

Stoke Therapeutics Trading Up 4.5%

The company has a market cap of $1.31 billion, a PE ratio of 28.23 and a beta of 1.14. The business has a fifty day moving average of $18.03 and a 200-day moving average of $12.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the transaction, the insider owned 18,469 shares in the company, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total value of $925,899.48. Following the transaction, the director owned 91,585 shares of the company's stock, valued at $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 107,719 shares of company stock worth $2,063,359. Company insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Siren L.L.C. raised its stake in Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock valued at $14,945,000 after buying an additional 247,347 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Stoke Therapeutics by 117.0% in the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company's stock worth $174,000 after purchasing an additional 14,118 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Stoke Therapeutics in the 1st quarter worth $719,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.